Find in Library

618 Phase 1 clinical trial evaluating the safety, biologic and anti-tumor activity of the novel STING agonist IMSA101 administered both as monotherapy and in combination with PD-(L)1 checkpoint inhibitors

oleh: Syed Kazmi, Lijun Sun, Angela Alistar, Ezra Cohen, Timothy Yap, Devalingam Mahalingam, Justin C Moser, Edward Garmey, Teresa Mooneyham